U.S. fears over compulsory licence for anti-cancer drug allayed
Issuing licence is totally compliant with multilateral agreements: Sharma
India, on Wednesday, conveyed to the U.S. that it had not violated any multilateral trade agreement by issuing compulsory licence for Bayer’s patented anti-cancer drug Nexavar to a local firm so as to make it affordable. It also asserted that such a move should not be seen as routine by the U.S. The message was conveyed by Commerce and Industry Minister Anand Sharma to U.S. Under Secretary for Economic Growth, Energy and Environment Rober Hormats, who raised concerns over the matter during a meeting here, according to an official.